Actuate Therapeutics ACTU
NASDAQ ACTU
$0.82 -0.07 (-7.87%)
At close: Oct 2, 2026 · 4:00 PM EDT

Actuate Therapeutics (ACTU) Return on Assets [ROA] (2024 - 2026)

Updated

Actuate Therapeutics (ACTU) recorded Return on Assets [ROA] of -216.04% in Q2 2026, up 203.60 percentage points from -419.63% a year earlier.

Analysis

Actuate Therapeutics (ACTU) Return on Assets [ROA] (2024 - 2026) Analysis & Trends

For FY2025, Actuate Therapeutics reported Return on Assets [ROA] of -190.35%, up 214.99 percentage points from FY2024.

  • Across earlier years, Return on Assets [ROA] came in at -405.35% in FY2024.
  • Quarterly Return on Assets [ROA] has ranged from -419.63% in Q2 2025 to -140.02% in Q4 2025 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 20.64%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 10.47%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 4.65%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 2.45%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 28.37%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 9.10%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 9.29%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -6.13%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 2.14%
10 Actuate Therapeutics 19.69 Mn 19.69 Mn - -216.04%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -216.04%
Dec 31, 2025 -140.02%
Sep 30, 2025 -195.44%
Jun 30, 2025 -419.63%
Mar 31, 2025 -340.70%
Dec 31, 2024 -211.67%
Sep 30, 2024 -326.03%
API Access

Actuate Therapeutics Return on Assets [ROA] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=ACTU&period=max&api_key=YOUR_API_KEY